Physician profile
Pedro Barros
NPI 1649276494
$3,448.59
in general payments reported to CMS, 2019-2025
19 companies · $950 in 2025
The $950 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $132 · 2020: $93.62 · 2021: $246 · 2022: $424 · 2023: $660 · 2024: $943 · 2025: $950.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,553.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,553.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,866.09 | 2019-2025 | Rinvoq, Linzess, Viberzi |
| Phathom Pharmaceuticals, INC. | $278.92 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $232.78 | 2024-2025 | Rezdiffra, Resmetirom |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $206.47 | 2023-2025 | Xifaxan, Trulance |
| Ardelyx, INC. | $169.84 | 2024-2025 | Ibsrela |
| Gilead Sciences, INC. | $112.61 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $100.30 | 2019-2024 | Gattex, Eohilia |
| Celgene Corporation | $80.47 | 2021-2024 | Zeposia |
| Pfizer INC. | $75.35 | 2019-2023 | |
| Lilly USA, LLC | $62.98 | 2024 | Omvoh |
| Ferring Pharmaceuticals INC. | $55.44 | 2022-2024 | Rebyota |
| Genzyme Corporation | $52.77 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $28.29 | 2023 | Dupixent |
| Romark Laboratories, Lc | $22.77 | 2019 | |
| Qol Medical, LLC | $22.01 | 2025 | Sucraid |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $21.36 | 2025 | Vowst |
| Ironwood Pharmaceuticals, INC | $21.28 | 2022 | |
| Fresenius Kabi USA, LLC | $20.63 | 2023 | Idacio |
| Merck Sharp & Dohme LLC | $18.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pedro Barros listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.